Margin as the measure
Elementis (LSE:ELM) has set itself a medium-term target of adjusted operating margins above 23%, and its first-half results for 2026 show it reaching that level. The question is how the speciality chemicals group achieved the improvement, which of its two businesses contributed most, and what it is doing with the cash that a recent disposal released.
A two-segment chemicals group
Elementis, listed on the London Stock Exchange under the code ELM, makes speciality additives and ingredients and reports in US dollars. Its Personal Care segment supplies ingredients for cosmetics, skincare and suncare, including hectorite-based products, as well as antiperspirant actives. Its Coatings segment supplies additives that modify the flow and performance of paints and coatings, along with an energy Business serving the oil and gas sector. The company runs a strategy called Elevate Elementis, aimed at growth through innovation and cost efficiency.
Half-year results
On 30 July 2026, Elementis reported results for the six months to 30 June 2026. Revenue was $318.2 million, with organic growth of 4.7% at constant currency. Adjusted operating profit rose 16.4% to $73.2 million and the adjusted operating Margin widened by 140 basis points to 23.0%. Statutory operating profit increased 18.6% to $65.7 million, and adjusted Diluted Earnings per Share rose 28.8% to 8.5 cents. Chief executive Luc van Ravenstein said: "Revenue in the first half is up 5% organic constant currency, profits are up 16% and margins are also improving while net Debt is close to our 1x target."
Coatings, the larger segment, generated revenue of $209.0 million with organic growth of 5.6% and an adjusted Operating Margin of 20.7%; the company said performance was good across regions, with energy particularly healthy, and that six new products were launched. Personal Care revenue was $109.2 million, up 2.9% organically, with a margin of 38.1%, helped by cosmetics pricing, antiperspirant volumes and the Alchemy acquisition. The company said Elevate Elementis delivered $0.5 million of net savings in the half after extra R&D spending, bringing cumulative net savings to $6.5 million of a $10 million medium-term target.
Disposal, buyback and balance sheet
Elementis said it sold its pharmaceutical Manufacturing business to Associated British Foods on 2 June 2026, at an Enterprise value of €34.3 million, with net cash proceeds of about €31 million and a book gain of $13.0 million. It then launched a £25 million buyback, announced on 3 June. The most recent notice, on 28 September 2026, reported the purchase of 337,500 shares between 21 and 25 September, after which there were 565,476,550 voting rights and 3,026,535 shares in treasury. Net debt fell to $163.8 million, equal to 1.1 times EBITDA, free Cash Flow was $13.3 million, and the Interim Dividend rose 15.4% to 1.5 cents. Other medium-term targets include mid-single-digit revenue growth and a return on Capital employed above 30%. On 16 September 2026, Christine Soden, who chairs the audit committee, was confirmed as senior independent director.
Risks and uncertainties
Free cash flow of $13.3 million was relatively modest relative to profit, and continued Buybacks will absorb some of the cash generated. Coatings Demand is tied to industrial and construction activity and the energy business to drilling activity, both of which can be cyclical. Personal Care growth was slower in the half, so new product launches need to gain traction. The company also faces currency effects, given its dollar reporting and sterling-denominated buyback.
Conclusion
Elementis reported that its margin reached 23.0% through a combination of higher Coatings volumes, Personal Care pricing and mix, and savings from its Elevate programme. With Leverage close to its 1x target, it is using proceeds from the pharmaceutical sale to fund buybacks, and it said it remains confident of full-year performance in line with expectations.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...